Clinical operations and pharmacovigilance are often managed in parallel — but in early-phase and complex trials, that separation can create avoidable risk. Delayed safety decisions, protocol amendments, inconsistent safety data handling, and added pressure on sites can directly affect both patient safety and development timelines.
In this on-demand webinar, experts from Ergomed Clinical Research and PrimeVigilance explore how earlier integration across clinical operations, medical monitoring, and pharmacovigilance can strengthen study oversight from the outset. You’ll learn how a more connected approach across protocol strategy, trial conduct, individual case safety report handling, signal and risk management can help sponsors reduce downstream risk, improve decision-making, and keep complex studies on track.
Key takeaways include:
- Why separating clinical operations and safety oversight creates avoidable risk in clinical development
- Where silos most often create issues, including delayed decisions, protocol amendments, inconsistent safety data handling, signal and risk management gaps, and added site burden
- What integrated planning looks like across study design, medical monitoring, pharmacovigilance, and trial conduct
- How earlier collaboration can support stronger decision-making, operational readiness, and timeline protection
- Practical ways to reduce downstream risk while improving both patient safety and study efficiency